every 21 days, concurrent with radiotherapy is more effective with an increase in overall 5 year survival of 18%, and a reduction in the risk of death by 62.5% (HR 0.375, p = 0.03). It was also overall less toxic than weekly cisplatin treatment. For instance, grade 3-4 neutropenia was approximately half of that seen with the weekly regimen (Ryu et al., 2011) .
The results of Nagy et al. were similar, showing that daily cisplatin, 20 mg/m 2 for 5 days every three weeks has a superior five-year local relapse-free survival (p b 0.01), lesser toxicity, and a similar 5-year survival rate compared with the standard weekly cisplatin treatment (Nagy et al., 2012) . Based on the meta-analysis of Petrelli et al. and the 8 RCTs comparing single agent weekly cisplatin to other regimens (see Table 1 ), it is reasonable to conclude that weekly cisplatin is no longer the only option for chemosensitization with radiotherapy for locally advanced cervical cancer. We hope that a more comprehensive meta-analysis in the future will include some of these other trials that show a trend toward benefit for alternatives to weekly platinum. For instance, Pu et al. showed an intriguing trend toward improved 5 year local recurrence (79.3% versus 69.3%, p = 0.061) and overall survival (82.8% versus 74.3%, p = 0.098) Pu et al., 2013 . It is likely that had a one tail test been used, the results would have been statistically significant. These slightly under powered studies are ideally suited for inclusion in meta-analyses.
Over more than 30 years, chemosensitization for cervical cancer has seen little change. The time between an early report of benefit (circa 1984) to widespread adoption (1999) of chemosensitization, may have cost the lives of many women who could have benefited from the improvement in overall survival. We are again at a pivotal time when alternatives to a comfortable standard are being challenged. Given the widespread large number of cases of new cervical cancer in the world today, any delay in adopting new advances may be costly.
Further studies are warranted to determine the optimal doublet or other alternatives to single agent weekly cisplatin. Further studies are not needed to justify continued use of single agent cisplatin. Let's not relive 1984. ; CR pathologic: complete pathologic response rate; CT: chemotherapy; D1,D8: day 1, day 8; DFS: disease free survival; Gem: gemcitabine; HDR: high dose rate; HU: hydroxyurea; IV: intravenous; mos: months; N/A: not applicable; Op: operation; OS: overall survival; PFS: progression free survival; PO: orally; q28d: every 28 days; RFS: recurrence free survival; wks: weeks; DOC: docetaxel; yr: year.
a Those with no evidence of tumor cells or residual microscopic disease in the absence of any or intermediate-or high-risk factors for recurrence (near-complete).
